title: Hyperuricemia, hypertension, and proteinuria associated with high-altitude polycythemia.
abstract: Chronic exposure to high altitude is associated with the development of erythrocytosis, proteinuria, and, in some cases, hyperuricemia. We examined the relationship between high-altitude polycythemia and proteinuria and hyperuricemia in Cerro de Pasco, Peru (altitude, 4,300 m). We studied 25 adult men with hematocrits less than 65% and 27 subjects with excessive erythrocytosis (EE; hematocrit > 65%) living in Cerro de Pasco, Peru and compared them with 28 control subjects living in Lima, Peru (at sea level) and after 48 hours of exposure to high altitude. Serum urate levels were significantly elevated in patients with EE at altitude, and gout occurred in 4 of 27 of these subjects. Urate level strongly correlated with hematocrit (r = 0.71; P < 0.0001). Urate production (24-hour urine urate excretion and urine urate-creatinine ratio) was increased in this group compared with those at sea level. Fractional urate excretion was not increased, and fractional lithium excretion was reduced, in keeping with increased proximal reabsorption of filtrate. Significantly higher blood pressures and decreased renin levels in the EE group were in keeping with increased proximal sodium reabsorption. Serum urate levels correlated with mean blood pressure (r = 0.50; P < 0.0001). Significant proteinuria was more prevalent in the EE group despite normal renal function. Hyperuricemia is common in subjects living at high altitude and associated with EE, hypertension, and proteinuria. The increase in uric acid levels appears to be caused by increased urate generation secondary to systemic hypoxia, although a relative impairment in renal excretion also may contribute.
authors.affiliation: Department of Medicine and Laboratory Medicine, University of Washington Medical Center, Seattle, WA, USA.
authors.forename: J Ashley
authors.initials: JA
authors.lastname: Jefferson
authors.forename: Elizabeth
authors.initials: E
authors.lastname: Escudero
authors.forename: Maria-Elena
authors.initials: ME
authors.lastname: Hurtado
authors.forename: Jackeline Pando
authors.initials: JP
authors.lastname: Kelly
authors.forename: Erik R
authors.initials: ER
authors.lastname: Swenson
authors.forename: Mark H
authors.initials: MH
authors.lastname: Wener
authors.forename: Michel
authors.initials: M
authors.lastname: Burnier
authors.forename: Marc
authors.initials: M
authors.lastname: Maillard
authors.forename: George F
authors.initials: GF
authors.lastname: Schreiner
authors.forename: Robert B
authors.initials: RB
authors.lastname: Schoene
authors.forename: Abdias
authors.initials: A
authors.lastname: Hurtado
authors.forename: Richard J
authors.initials: RJ
authors.lastname: Johnson
mesh_terms: D000328:Adult; D000531:Altitude; D016022:Case-Control Studies; D006400:Hematocrit; D006801:Humans; D006973:Hypertension / Q000209:etiology*; D008297:Male; D010100:Oxygen / Q000097:blood; D011086:Polycythemia / Q000150:complications* / Q000378:metabolism / Q000628:therapy; D011507:Proteinuria / Q000209:etiology*; D012964:Sodium / Q000378:metabolism; D014527:Uric Acid / Q000097:blood*
chemical_list: D014527:Uric Acid; D012964:Sodium; D010100:Oxygen